Recursion Pharmaceuticals (RXRX) Expected to Post Earnings on Wednesday

Key Points

• Recursion Pharmaceuticals is expected to report Q3 2026 results before the market opens on November 4. Analysts forecast a loss of $0.219 per share and revenue of $14.81 million; the earnings call is scheduled for November 3 at 8:00 a.m. ET.
• The company’s previous quarter fell short of expectations, reporting a $0.25-per-share loss and $7.67 million in revenue versus estimates of a $0.24 loss and $10.97 million in revenue.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an $8.18 price target. RXRX recently traded around $4.05, while insiders have sold 157,408 shares worth approximately $643,576 over the past 90 days.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) is projected to post its Q3 2026 & Study Update results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.2190) per share and revenue of $14.81 million for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 & Study Update earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The business had revenue of $7.67 million for the quarter, compared to the consensus estimate of $10.97 million. During the same quarter last year, the company earned ($0.41) EPS. On average, analysts expect Recursion Pharmaceuticals to post ($0.93) EPS for the current fiscal year and ($0.87) EPS for the next fiscal year.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $4.05 on Wednesday. The company has a 50-day simple moving average of $3.69 and a 200-day simple moving average of $3.55. The firm has a market capitalization of $2.17 billion, a P/E ratio of -3.89 and a beta of 1.04. Recursion Pharmaceuticals has a 52 week low of $2.77 and a 52 week high of $6.25.

Insider Buying and Selling at Recursion Pharmaceuticals

In related news, CEO Najat Khan sold 22,408 shares of the business's stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total value of $78,876.16. Following the sale, the chief executive officer owned 2,072,890 shares of the company's stock, valued at $7,296,572.80. The trade was a 1.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 50,000 shares of the business's stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $4.84, for a total value of $242,000.00. Following the completion of the sale, the director directly owned 6,108,287 shares in the company, valued at approximately $29,564,109.08. This represents a 0.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 157,408 shares of company stock valued at $643,576. 6.65% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

RXRX has been the topic of a number of recent research reports. Morgan Stanley set a $5.90 target price on Recursion Pharmaceuticals in a research report on Friday, October 16th. Wall Street Zen raised Recursion Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday, October 17th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a report on Thursday, October 15th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Monday, October 19th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $8.18.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company's platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.